Navigation Links
New drug candidate prolongs the lives of pancreatic cancer patients
Date:7/20/2009

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

There's new hope, though, from the lab of Prof. Yoel Kloog, dean of Tel Aviv University's Faculty of Life Sciences. His drug compound Salirasib has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it.

"In our study, the mean survival of pancreatic cancer patients was 10.8 months better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting of the American Society of Clinical Oncology. His basic research offers the promise of a weapon to attack a broader range of mankind's most prevalent diseases, including lung, prostate and breast cancers as well as diabetes.

Blocking the Ras protein

Salirasib works by inhibiting a protein called Ras, which is known to be abnormally activated in one-third of human cancers. In cancer of the pancreas, mutant forms of Ras are found in up to 90% of all tumors. Salirasib's basic component, FTS, works to block the formation of cancer-promoting Ras nanoclusters, thus blocking a cascade of biochemical signals known as the "Ras signaling pathway" that allow Ras to wreak havoc on the body.

Early in the 1990s, many drug developers chased after a mechanism to inhibit Ras by targeting enzymes that modify it, but they were unsuccessful. "The major developers gave up, claiming Ras is not targetable," says Prof. Kloog, "but our concept takes a different approach. Now that we've shown it works in human subjects, I am definitely excited no doubt about it." Prof. Kloog developed the Ras antagonist more than 15 years ago.

No toxic side effects

In the latest study, researchers tested for both toxicity and effectiveness. They gave 19 patients with advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed on average the number of months they would have lived on gentamiacine alone. There were no toxic side effects, such as heart or lung ailments. Tumor biopsies showed a significant reduction in Ras levels, suggesting that the drug is inhibiting the action of Ras in the tumor itself.

For this study, Salirasib was licensed by Concordia Pharmaceuticals, which collaborated with the Memorial Sloan Kettering Cancer Center, Johns Hopkins, the M.D. Anderson Cancer Center and other institutes in the United States.

If Phase II/III trials are successful, Prof. Kloog's drug will be the first successful Ras antagonist known to medical science. Salirabib could be medically available in as little as two years.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
9. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
10. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: